Back To: Home

January 19-23, 2015
PepTalk - San Diego, CA

February 7-11, 2015
SLAS2015 - Washington, DC

More Events

Genzyme signs manufacturing deal with Hospira
February 2010

CAMBRIDGE, Mass.—Biotechnology company Genzyme Corp. is contracting manufacturing for its key products to Hospira Inc. for an undisclosed amount, the company announced last month. The deal involves the manufacturing of the genetic disorder drugs Cerezyme, Fabrazyme, Myozyme and Thyrogen and follows a series of manufacturing problems at the company's facility in the Boston neighborhood of Allston. In June, Genzyme shut down the manufacturing plant to clean up viral contamination that had been slowing down production of two key drugs. The virus was not harmful to people and production restarted in September, though it cost the company millions in revenue. The deal with Hospira, which makes drug and medication delivery systems, calls for the initial term to expire on Dec. 31, 2015. There are options for a two-year extension. The deal is still subject to regulatory approval for manufacturing the products.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.